Concerns over the Aesica acquisition, combined with market weakness, have seen the share price down over 20% since the announcement. Although we share the view that Aesica may initially dilute Consort’s quality of earnings, it is expected to be materially earnings enhancing and the combined capabilities should be attractive to pharma customers, improving the longer-term growth prospects. Overall, therefore, we don’t think the rating for the combined group should be significantly l
22 Oct 2014
Getting into drugs!
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Getting into drugs!
Concerns over the Aesica acquisition, combined with market weakness, have seen the share price down over 20% since the announcement. Although we share the view that Aesica may initially dilute Consort’s quality of earnings, it is expected to be materially earnings enhancing and the combined capabilities should be attractive to pharma customers, improving the longer-term growth prospects. Overall, therefore, we don’t think the rating for the combined group should be significantly l